Michael Hayden, MB ChB, PhD — Chairman, Scientific Advisory Board

Dr. Michael Hayden is senior scientific advisor to the company and Chairman of Axovant’s newly established Scientific Advisory Board. Dr. Hayden is one of the world’s leading experts in the genetic basis of movement disorders and CNS drug development. He recently served as President of Global R&D and Chief Scientific Officer at Teva. Prior to Teva, he founded multiple biotechnology companies, including Aspreva Pharmaceuticals. He currently serves as Killam Professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine. Dr. Hayden played a key role in the discovery and development of GLYBERA®, the world’s first approved gene therapy product. He has received numerous awards including the Order of Canada, granted for his contributions to the understanding of Huntington’s disease and other genetic disorders. In 2008 he was named Canada’s Health Researcher of the Year and in 2017 he was inducted into the Canadian Medical Hall of Fame. Dr. Hayden received his MB ChB, PhD in Genetics, and DCH Diploma in Child Health from the University of Cape Town in South Africa. He completed his clinical training in internal medicine and clinical genetics at Harvard Medical School.

In December 2018, Axovant convened members of its Scientific Advisory Board under the leadership of Michael Hayden, MB ChB, PhD, chair of the Scientific Advisory Board. The meeting brought together leaders and pioneers in gene therapy and neurodegenerative disorders to have a productive set of discussions related to scientific, clinical and technical topics of strategic importance to Axovant. These discussions covered novel developments and improvements in lentiviral and AAV gene therapy technology, gene therapy approaches to neurodegenerative conditions and the future of gene editing.


Eleven Times Square, 33rd Floor
New York, NY 10036
United States

+1-833-AXOVANT (1-833-296-8268)

  • Axovant Gene Therapies LinkedIn
  • Axovant Gene Therapies Twitter
  • Axovant Gene Therapies Facebook


Viaduktstrasse 8
4051 Basel